Genomic landscape and clinical characteristics of patients (pts) with neuroendocrine prostate cancer (NEPC) with or without aggressive variant prostate cancer characterized by molecular signature (AVPC-MS).

作者：Hedyeh Ebrahimi, Regina Barragán-Carrillo, Miguel Zugman, Salvador Jaime‐Casas, Koral Shah, Daniela V. Castro, Benjamin Mercier, Zeynep Büşra Zengin, Luís Meza, Xiaochen Li, Joann Hsu, Peter D. Zang, Nazlı Dizman, Charles B. Nguyen, Abhishek Tripathi, Tanya B. Dorff, Sumanta Kumar Pal, Alex Chehrazi‐Raffle · 发表于：Journal of Clinical Oncology · 年份：2025 · DOI：10.1200/jco.2025.43.16_suppl.5087 · 被引用次数：2 · 研究领域：Prostate Cancer Treatment and Research、Prostate Cancer Diagnosis and Treatment、Radiopharmaceutical Chemistry and Applications

5087 Background: NEPC is a rare, aggressive subtype that can arise de novo or after treatment with androgen receptor inhibitors. Recent NEPC clinical trials have also included pts who have AVPC-MS (Aggarwal et al , ASCO 2024). However, the prevalence and clinical characteristics of NEPC with or without AVPC-MS need further investigation. Methods: The de-identified Tempus Lens dataset was used to retrieve records of pts diagnosed with NEPC. Pts were classified as having AVPC-MS if they had ≥2 alterations in TP53 , RB1 , and/or PTEN . Demographic and clinical characteristics were summarized using descriptive statistics and compared between individuals with and without AVPC-MS using chi-square and Fisher’s exact tests. The prevalence of genomic alterations between pts with and without AVPC-MS was compared using a two-proportions Z-test with False Discovery Rate (FDR) correction to account for multiple comparisons. Results: A total of 308 pts diagnosed with NEPC were identified and included in this analysis. Among them, 124 (40.3%) had RB1 , 141 (45.8%) had TP53 , and 64 (20.8%) had PTEN alterations. A total of 109 (35.4%) pts met the criteria for AVPC-MS whereas 81 (26.2%) pts harbored only a single alteration in either TP53 , RB1 , or PTEN and thus did not meet the criteria. The proportion of individuals aged >60 years was similar between those with and without AVPC-MS (56.0% vs. 58.8%, p=0.70). Additionally, 48.6% of pts with AVPC-MS were white, compared to 60.8% of those w...